ECMO and Short-term Support for Cardiogenic Shock in Heart Failure

AbstractPurpose of ReviewThis review aims to discuss the role of ECMO in the treatment of cardiogenic shock in heart failure.Recent FindingsTrials done previously have shown that IABP does not improve survival in cardiogenic shock compared to medical treatment, and that neither Impella 2.5 nor TandemHeart improves survival compared to IABP. The “IMPRESS in severe shock” trial compared Impella CP with IABP and found no difference in survival. A meta-analysis of cohort studies comparing ECMO with IABP showed 33% improved 30-day survival with ECMO (risk difference 33%; 95% CI 14–52%;p = 0.0008; NNT 3).SummaryECMO is indicated in medically refractory cardiogenic shock. ECMO can be considered in cardiogenic shock patients with estimated mortality of more than 50%. ECMO is probably the MCS of choice in cardiogenic shock with; biventricular failure, respiratory failure, life-threatening arrhythmias and cardiac arrest.
Source: Current Cardiology Reports - Category: Cardiology Source Type: research